[go: up one dir, main page]

MX366726B - Composiciones de liberacion controlada y metodos para su uso. - Google Patents

Composiciones de liberacion controlada y metodos para su uso.

Info

Publication number
MX366726B
MX366726B MX2014010274A MX2014010274A MX366726B MX 366726 B MX366726 B MX 366726B MX 2014010274 A MX2014010274 A MX 2014010274A MX 2014010274 A MX2014010274 A MX 2014010274A MX 366726 B MX366726 B MX 366726B
Authority
MX
Mexico
Prior art keywords
methods
controlled release
release compositions
composition
amount
Prior art date
Application number
MX2014010274A
Other languages
English (en)
Other versions
MX2014010274A (es
Inventor
Al Alawi Fadil
Bork Olaf
George Tucker Ian
Original Assignee
Bayer New Zealand Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49083030&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX366726(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer New Zealand Ltd filed Critical Bayer New Zealand Ltd
Publication of MX2014010274A publication Critical patent/MX2014010274A/es
Publication of MX366726B publication Critical patent/MX366726B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pregnancy & Childbirth (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Lubricants (AREA)

Abstract

La presente invención se refiere a una composición, donde la composición incluye una cantidad terapéuticamente eficaz de al menos un agente activo y una base que incluye una cantidad de sílice coloidal, al menos un aceite y al menos un tensioactivo, donde la viscosidad de la composición se encuentra por debajo de 1000 mPas a una velocidad de cizallamiento de 100 1/s y a una temperatura de 20 °C.
MX2014010274A 2012-02-27 2013-02-27 Composiciones de liberacion controlada y metodos para su uso. MX366726B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ59844312 2012-02-27
PCT/NZ2013/000022 WO2013129944A1 (en) 2012-02-27 2013-02-27 Controlled release compositions and their methods of use

Publications (2)

Publication Number Publication Date
MX2014010274A MX2014010274A (es) 2014-09-16
MX366726B true MX366726B (es) 2019-07-22

Family

ID=49083030

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014010274A MX366726B (es) 2012-02-27 2013-02-27 Composiciones de liberacion controlada y metodos para su uso.

Country Status (26)

Country Link
US (1) US10828311B2 (es)
EP (1) EP2819699B2 (es)
JP (1) JP6271443B2 (es)
KR (1) KR102100271B1 (es)
CN (2) CN104244983A (es)
AU (1) AU2013201147A1 (es)
BR (1) BR112014021218A2 (es)
CA (1) CA2865555C (es)
CL (1) CL2014002227A1 (es)
CO (1) CO7061074A2 (es)
CR (1) CR20140396A (es)
DK (1) DK2819699T3 (es)
DO (1) DOP2014000195A (es)
ES (1) ES2740958T5 (es)
HR (1) HRP20191412T1 (es)
HU (1) HUE045495T2 (es)
MX (1) MX366726B (es)
NI (1) NI201400096A (es)
PH (1) PH12014501919B1 (es)
PL (1) PL2819699T5 (es)
PT (1) PT2819699T (es)
RU (1) RU2627429C2 (es)
SI (1) SI2819699T1 (es)
SV (1) SV2014004796A (es)
WO (1) WO2013129944A1 (es)
ZA (1) ZA201406267B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2874624T1 (sl) * 2012-07-17 2020-02-28 Bayer New Zealand Limited Formulacije antibiotikov za injektiranje in postopek njihove uporabe
SG11201906616VA (en) * 2017-01-20 2019-08-27 M et P Pharma AG Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants
EP3934618A1 (en) * 2019-03-06 2022-01-12 Zoetis Services LLC Ready-to-use injectable formulations
CN116763783B (zh) * 2022-03-09 2025-08-12 成都倍特药业股份有限公司 一种氯唑西林钠组合物及其制备方法
CN114847280A (zh) * 2022-07-07 2022-08-05 山东实力农业股份有限公司 一种包含脂肽的生物刺激剂组合物的制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3234086A (en) 1961-05-12 1966-02-08 Univ Iowa State Res Found Inc Antibiotic bloat control composition and method of using same
US3252859A (en) * 1962-10-24 1966-05-24 Masti Kure Company Inc Colloidal silica-oil composition and method of using same
GB1547164A (en) 1975-08-14 1979-06-06 Beecham Group Ltd Veterinary compositions
IL58461A0 (en) 1978-10-27 1980-01-31 Beecham Group Ltd Intramammary compositions comprising a clavulanic acid salt
IL58462A0 (en) 1978-10-27 1980-01-31 Beecham Group Ltd Intramammary compositions comprising a penicillin
EP0058015A3 (en) 1981-02-05 1982-08-25 Beecham Group Plc Treatment of infections
JPS60169431A (ja) * 1984-02-14 1985-09-02 Nippon Zenyaku Kogyo Kk β−ラクタム環を有する化合物を含有する安定な抗菌剤及びその製造法
JPS6289617A (ja) * 1985-08-12 1987-04-24 ウイリアム　ガウフ　タツカ− 薬剤組成物およびその調製方法
EP0212875A3 (en) 1985-08-12 1988-06-15 William Gough Tucker Medicinal composition and method of making same
GB8531609D0 (en) 1985-12-23 1986-02-05 Beecham Group Plc Compounds
US4980175A (en) 1989-01-03 1990-12-25 Leonard Chavkin Liquid orally administrable compositions based on edible oils
US6060592A (en) 1990-01-11 2000-05-09 Isis Pharmaceuticals, Inc. Pyrimidine nucleoside compounds and oligonucleoside compounds containing same
US5122377A (en) 1990-11-19 1992-06-16 A.H. Robins, Company, Incorporated Oral delivery system for veterinary drugs
GB2338896B (en) * 1998-07-02 2003-05-21 Reckitt & Colmann Prod Ltd Chewable Capsules
US20020009478A1 (en) 1998-08-24 2002-01-24 Douglas Joseph Dobrozsi Oral liquid mucoadhesive compositions
US6787342B2 (en) * 2000-02-16 2004-09-07 Merial Limited Paste formulations
US20040033938A1 (en) * 2000-09-12 2004-02-19 Britten Nancy J. Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
WO2003063877A1 (en) 2002-02-01 2003-08-07 Akzo Nobel N.V. Cefquinome composition for intra-mammary administration in cattle
GB2398005B (en) 2002-02-20 2005-09-14 Strides Arcolab Ltd Orally administrable pharmaceutical formulation
WO2004032899A1 (en) * 2002-10-08 2004-04-22 Orchid Chemicals & Pharmaceuticals Ltd. Antibiotic formulation for intramammary administration in milking animals
DE60320034T2 (de) 2002-12-16 2009-05-14 Intervet International Bv Behandlung von mastitis mit einer kombination aus prednisolon und cephalosporin
US20080153894A1 (en) * 2002-12-19 2008-06-26 Pharmacia Corporation Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
US7842791B2 (en) 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
AU2002364023A1 (en) 2002-12-26 2004-07-22 Solution Biosciences, Inc. Compositions and methods for control of bovine mastitis
WO2004082679A1 (ja) 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited 放出制御組成物
WO2005117844A2 (en) 2004-05-21 2005-12-15 Industrial Science & Technology Network, Inc. Mucoadhesive nanocomposite delivery system
WO2006008640A1 (en) * 2004-07-15 2006-01-26 Pharmacia & Upjohn Company Llc Non-aqueous suspension containing a drug having an unpleasant taste
KR100822519B1 (ko) 2005-02-15 2008-04-16 주식회사종근당 위장 내에서 제어방출되는 단일 매트릭스 정제
DE102007055341A1 (de) * 2007-11-19 2009-05-20 Bayer Animal Health Gmbh Stabilisierung öliger Suspensionen enthaltend hydrophobe Kieselsäuren
DK3064217T3 (en) * 2009-01-06 2018-05-28 Galenagen Llc COMPOSITIONS COMPREHENSIVE PROTEASE, AMYLASE AND LIPASE FOR USE IN TREATMENT OF STAPHYLOCOCCUS AUREUS INFECTIONS
JP2012514604A (ja) * 2009-01-06 2012-06-28 キュレロン リミテッド ライアビリティ カンパニー 大腸菌（Ｅ．ｃｏｌｉ）による経口感染の治療または予防のための組成物および方法
WO2011009020A2 (en) * 2009-07-16 2011-01-20 Mallinckrodt Inc. Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
BRPI1002601E2 (pt) * 2010-06-01 2020-06-30 Embrapa Pesquisa Agropecuaria composição nanoestruturada de uso veterinário para administração de fármacos

Also Published As

Publication number Publication date
PH12014501919A1 (en) 2014-11-24
AU2013201147A1 (en) 2013-09-12
PL2819699T3 (pl) 2019-11-29
NI201400096A (es) 2014-11-28
RU2627429C2 (ru) 2017-08-08
JP2015508098A (ja) 2015-03-16
MX2014010274A (es) 2014-09-16
US10828311B2 (en) 2020-11-10
CR20140396A (es) 2014-10-29
SV2014004796A (es) 2017-05-12
PT2819699T (pt) 2019-08-21
KR20140126340A (ko) 2014-10-30
CN104244983A (zh) 2014-12-24
SI2819699T1 (sl) 2019-11-29
KR102100271B1 (ko) 2020-04-14
CO7061074A2 (es) 2014-09-19
RU2014135524A (ru) 2016-04-20
EP2819699A1 (en) 2015-01-07
EP2819699B2 (en) 2024-10-16
DOP2014000195A (es) 2014-10-31
EP2819699A4 (en) 2015-10-28
PH12014501919B1 (en) 2023-07-19
BR112014021218A2 (pt) 2020-10-27
CL2014002227A1 (es) 2015-01-09
DK2819699T3 (da) 2019-08-12
HRP20191412T1 (hr) 2019-11-15
CN110604819A (zh) 2019-12-24
PL2819699T5 (pl) 2025-11-12
ES2740958T5 (en) 2025-04-03
ZA201406267B (en) 2018-05-30
EP2819699B1 (en) 2019-05-22
ES2740958T3 (es) 2020-02-07
WO2013129944A1 (en) 2013-09-06
CA2865555A1 (en) 2013-09-06
HUE045495T2 (hu) 2019-12-30
US20150045337A1 (en) 2015-02-12
CA2865555C (en) 2021-01-12
JP6271443B2 (ja) 2018-01-31

Similar Documents

Publication Publication Date Title
MX362655B (es) Composiciones cosmeticas.
IN2014MN01779A (es)
EP3957711A3 (en) Detergent composition comprising amylase and protease variants
MX2021002406A (es) Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica.
BR112012022101A2 (pt) agente para melhorar a deposição de óleo sobre os cabelos.
BR112017009277A2 (pt) compostos de silicone
GB201020193D0 (en) Glucan compositions
WO2013130898A3 (en) Stabilizing agents and methods of use thereof
MX2015009397A (es) Detergente.
EA201291372A1 (ru) Фармацевтическая композиция, содержащая дроспиренон, и набор для предупреждения зачатия
PH12014501919B1 (en) Controlled release compositions and their methods of use
TW201613630A (en) Pharmaceutical compositions
BR112014005190A2 (pt) composições em microcápsula compreendendo gelificantes de di-amido ajustáveis por ph
MX2012013078A (es) Composiciones antimicrobianas liquidas de baja formacion de espuma, modificadas reologicamente, y sus metodos de uso.
MX2015008021A (es) Composiciones y metodos para administracion transdermica de hormonas y otros agentes medicos.
IN2014KN02990A (es)
PE20200478A1 (es) Nuevas formulaciones y composiciones de cannabis en comprimidos y metodos para su elaboracion
EP2576536A4 (en) HEMATOPOETIC PROSTAGLANDIN D2 SYNTHASE INHIBITORS
MX2015009323A (es) Composicion que comprende un antagomir encapsulado.
EP2910247A4 (en) COMPOSITIONS FOR THE AVOIDANCE OR TREATMENT OF SKIN ALLERGIES WITH GPCR19 SUBSTANCES AS ACTIVE AGENTS
MX369228B (es) Revestimientos de geomembranas a altas temperaturas y composiciones de lote maestro.
EA201391214A1 (ru) Композиции, содержащие алкилалкоксисульфонаты, для производства термостабильных пен
MX379679B (es) Composiciones para el cuidado personal.
SA519401957B1 (ar) تركيب بيروكسيد ثنائي ألكيل لتعديل انسياب متعدد بروبلين في الحالة المنصهرة
MX2014014524A (es) Composiciones que comprenden calcogenuros y metodos relacionados.

Legal Events

Date Code Title Description
FG Grant or registration